Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDR001 combination safety and pharmacodynamics study in advanced solid tumors
NL-OMON47909Phase 1Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2016
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of spartalizumab, LCL161, everolimus, panobinostat, siremadlin and 1 more in colorectal cancer (CRC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC) and 1 more (5 arms), sponsored by Novartis. Primary endpoints: Adverse events, Dose-limiting toxicities and 2 more. Started Oct 2016; status: active, not recruiting.
02
Drugs
spartalizumabLCL161everolimuspanobinostatsiremadlin
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON47909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47909.